New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Launched by CARDIOLOGY PRAGUE · Aug 7, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking for new ways to detect heart problems caused by chemotherapy, specifically in women undergoing treatment for breast cancer. The goal is to find new "biomarkers," which are substances in the body that can help doctors identify heart damage early on. Detecting these issues sooner can lead to faster treatment, which may help restore heart function and improve overall health.
To participate in the trial, women aged 65 to 74 who are being treated for breast cancer with chemotherapy known to potentially harm the heart may be eligible. However, those with a history of heart disease will not be included. If you join the study, you can expect to provide samples and possibly undergo tests that help researchers learn more about how to identify heart risks earlier. This research could ultimately lead to better care for breast cancer patients receiving chemotherapy.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Breast cancer
- • Chemotherapy with a known cardiotoxic side effect
- Exclusion Criteria:
- • Known cardiovascular disease
About Cardiology Prague
Cardiology Prague is a leading clinical trial sponsor dedicated to advancing cardiovascular research and improving patient outcomes. Based in the heart of Prague, the organization specializes in the design, management, and execution of innovative clinical trials focused on a range of cardiovascular conditions. With a commitment to scientific rigor and patient safety, Cardiology Prague collaborates with esteemed medical institutions and healthcare professionals to facilitate groundbreaking studies that contribute to the development of new therapies and enhance clinical practices in cardiology. Their expertise and strategic approach ensure the successful delivery of high-quality research outcomes that support the evolving needs of the cardiovascular community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Prague, , Czechia
Prague, , Czechia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported